XRTX PAID ADVERTORIAL *

XORTX Therapeutics Inc. – Developing Breakthrough Therapies for Gout and Progressive Kidney Disease Through Late-Stage Clinical Programs, Proprietary IP, and Multi-Billion-Dollar Market Opportunities

Focused on advancing proprietary uric acid–lowering and kidney disease therapies targeting large underserved global markets, XORTX Therapeutics Inc. is developing a diversified late-stage pipeline designed to address significant unmet medical needs across gout, ADPKD, renal fibrosis, and progressive kidney disease while pursuing near-term clinical, regulatory, and commercialization milestones.

The owners of IR Agency LLC who also are the publishers of this Advertorial have been paid Two Million Five Hundred Thousand Dollars Cash ($2,500,000) via bank wire transfer directly from the Issuer XORTX Therapeutics Inc. (NASDAQ: XRTX) for a 10 individual Marketing Days of distribution of marketing program regarding XRTX with a start date of 9/08/2026. This Advertorial is a part of that marketing program. The owners do not own stock in XRTX. See our important Notice and Disclaimer below for a detailed discussion on compensation.
XORTX Therapeutics Inc. (NASDAQ: XRTX)

📋 Investor Overview

XORTX Therapeutics Inc. (NASDAQ: XRTX) is a late-stage clinical pharmaceutical company focused on developing innovative therapies targeting gout, progressive kidney disease, renal fibrosis, diabetic nephropathy, and acute kidney injury associated with viral infections. The company’s programs are designed to address significant unmet medical needs across large and underserved global healthcare markets.

XORTX is advancing a diversified pipeline that includes XRx-026 for gout, XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), VB4-P5 for renal fibrosis, XRx-101 for acute kidney injury and respiratory virus-associated complications, and XRx-225 for Type 2 Diabetic Nephropathy. [i] [ii]

The company’s strategic focus combines late-stage clinical development, proprietary uric acid–lowering technologies, precision medicine research, and expanding intellectual property assets designed to support long-term commercialization opportunities and shareholder value creation.

With multiple near-term clinical and regulatory milestones, expanding pipeline depth, recent strategic acquisitions, and growing exposure to multi-billion-dollar kidney disease and gout markets, XORTX is positioning itself as an emerging innovator in renal and metabolic disease therapeutics.

XORTX Therapeutics Inc. (NASDAQ: XRTX) Medical Innovation

* See our Important Notice and Disclaimer below for a detailed discussion on compensation, risks, the risks associated with forward looking statements, the need to seek the advice of a professional investment advisor before investing, and more.

⭐ Highlights

Key Highlights

01

Late-Stage Clinical Pipeline

XORTX Therapeutics Inc. is advancing multiple therapeutic programs targeting gout, ADPKD, renal fibrosis, and progressive kidney disease with near-term regulatory and development milestones.

02

Large Market Opportunity

Programs target multi-billion-dollar global markets with significant unmet medical needs, including gout, chronic kidney disease, and rare kidney disorders.

03

Proprietary Drug Platform & IP Portfolio

XORTX has developed proprietary uric acid–lowering formulations and a growing intellectual property portfolio focused on xanthine oxidase inhibition and kidney disease therapeutics.

04

Near-Term Commercialization Pathway

Lead gout therapy XRx-026 is positioned near the NDA stage, supporting a potential pathway toward commercialization and revenue generation.

05

Expanding Pipeline Through Strategic Acquisitions

The acquisition of the VB4-P5 anti-fibrotic kidney disease program expands XORTX’s pipeline into fibrosis-focused therapies and broadens long-term growth opportunities.

🔗 Strategic Pipeline Expansion

XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

• VB4-P5 – novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease

“The acquisition of the VB4-P5 program strengthens XORTX’s strategic focus on developing innovative therapies for progressive kidney disease while expanding the company’s pipeline with a new technological direction. XORTX believes this novel agent has the potential to become an important treatment for mid-to-late stage chronic kidney disease, helping slow disease progression and associated fibrosis.”

Dr. Allen Davidoff
Dr. Allen Davidoff Chief Executive Officer of XORTX Therapeutics Inc. [iii]
💡 Challenge & Response

Addressing Large Underserved Markets in Gout and Progressive Kidney Disease

The Problem

Critical Unmet Medical Needs

Millions of individuals globally suffer from gout, chronic kidney disease (CKD), ADPKD, diabetic nephropathy, renal fibrosis, and acute kidney injury, while many currently available therapies remain limited, expensive, poorly tolerated, or associated with significant safety concerns.

In the United States alone, approximately 7 million patients have been diagnosed with gout [i], while nearly 47 million people [i] are estimated to have elevated uric acid levels linked to inflammatory and metabolic complications. An estimated 3–5% of gout patients are unable to tolerate allopurinol [i], the current standard-of-care therapy, creating a significant unmet treatment gap following safety concerns and FDA black-box warnings associated with febuxostat.

Chronic kidney disease affects an estimated 35–37 million [i] individuals in the United States, while approximately 160,000 patients [i] in the U.S. are diagnosed with Autosomal Dominant Polycystic Kidney Disease (ADPKD), a progressive genetic disorder often leading to kidney failure and cardiovascular complications. Current treatment options remain limited, with some therapies carrying annual treatment costs exceeding $156,000 [i] and black-box safety warnings.

Kidney fibrosis represents another major unmet medical challenge and is considered a key driver of CKD progression. Despite affecting millions of patients globally, there are currently no approved therapies specifically designed to reverse or directly target kidney fibrosis progression.

Solution

XORTX’s Therapeutic Platform

XORTX Therapeutics Inc. (NASDAQ: XRTX) is developing a diversified pipeline of proprietary therapeutic programs designed to target aberrant purine metabolism, elevated uric acid, inflammation, fibrosis, and progressive kidney damage across multiple large-market and orphan disease indications.

The company’s pipeline includes XRx-026 for gout, XRx-008 for ADPKD, VB4-P5 for renal fibrosis, XRx-101 for acute kidney injury associated with respiratory viral infections, and XRx-225 for diabetic nephropathy. Through proprietary uric acid–lowering technologies, expanding intellectual property assets, precision medicine research, and late-stage clinical development programs, XORTX is positioning its therapeutic platform to address significant unmet needs across multi-billion-dollar kidney disease and metabolic disorder markets.

💰 Market Opportunity

Targeting Multi-Billion-Dollar Markets Across Gout, Kidney Disease, and Renal Fibrosis

47M
Elevated Uric Acid Patients (U.S.)
~$2B
Addressable Gout Market (Annual)
37M
CKD Patients (U.S.)
$1-6B
ADPKD Peak Sales Potential

XORTX Therapeutics Inc. (NASDAQ:XRTX) is advancing therapeutic programs targeting large underserved markets across gout, ADPKD, chronic kidney disease, renal fibrosis, and diabetic nephropathy.

In the U.S. alone, approximately 47 million [i] individuals are estimated to have elevated uric acid levels, including nearly 7 million diagnosed gout patients and approximately 280,000 allopurinol-intolerant patients [i]. The addressable gout market is estimated at nearly $2 billion annually [i], with projected annual drug pricing between $6,000–$8,000 per patient [i]. XORTX’s lead gout therapy, XRx-026 [i], is targeting projected peak sales potential between $500 million and $1 billion [i], while febuxostat previously achieved approximately $500 million [i] in annual U.S. sales prior to FDA black-box safety concerns.

Chronic kidney disease affects approximately 35–37 million [i] Americans, while nearly 160,000 U.S. patients [i] are diagnosed with ADPKD. Current treatment options can exceed annual treatment costs of $156,000 [i], supporting significant commercial opportunities for new therapies targeting progressive kidney disease and renal fibrosis. XORTX estimates peak U.S. sales potential for its ADPKD program between $1 billion and $6 billion annually [i].

Renal fibrosis and diabetic nephropathy continue to represent major unmet medical markets with limited approved therapies, creating additional long-term growth opportunities for XORTX’s expanding proprietary therapeutic pipeline.

XORTX Therapeutics Inc. Well Positioned to Capture Significant Growth Opportunities Across Expanding Gout, Kidney Disease, ADPKD, and Renal Fibrosis Markets

* See our Important Notice and Disclaimer below for a detailed discussion on compensation, risks, the risks associated with forward looking statements, the need to seek the advice of a professional investment advisor before investing, and more.

🎯 Investment Thesis

Top Reasons to Have XRTX on Your Radar*

PRE-NDA Ready Lead Asset

XRx-026, XORTX’s proprietary gout therapy, is positioned at the PRE-NDA stage with multiple near-term regulatory milestones expected through 2027. [i]

Targeting a Significant Unmet Gout Market

XRx-026 is targeting a projected >$0.7B peak sales opportunity created following safety concerns and FDA black-box warnings associated with febuxostat. [i]

Late-Stage Clinical Validation

Multiple successful clinical studies involving more than 700 patients have demonstrated safety and efficacy of XORTX’s oxypurinol-based therapeutic platform. [i]

Exposure to Large Kidney Disease Markets

XRx-008 for ADPKD is advancing toward registration trials targeting a market opportunity estimated to exceed $5 billion. [i]

Expanding Renal Fibrosis Pipeline

The acquisition of the VB4-P5 anti-fibrotic kidney disease program expands XORTX’s pipeline into large chronic kidney disease and fibrosis markets with limited approved therapies. [i]

Multiple Near-Term Catalysts

Expected milestones include IND submissions, PK study results, CM&C validation completion, stability studies, and targeted NDA submission milestones. [i]

Comparable Multi-Billion-Dollar Industry Transactions

Recent sector acquisitions highlight growing strategic interest in gout and kidney disease therapeutics. [i]

  • Sobi acquisition of SEL-212 for up to $1.6B
  • Novartis acquisition of Regulus ADPKD asset for up to $1.7B

Proven Biotech Leadership Experience

XORTX leadership has prior company-building experience linked to: [i]

  • Cynapsus Therapeutics acquired for $624M
  • Trillium Therapeutics acquired for $2.2B

Strengthened Capital Position

XORTX recently completed a $5 million public offering intended to support operational growth, pipeline advancement, and investor awareness initiatives. [i]

Proprietary Platform with Expanding IP Portfolio

XORTX continues expanding its proprietary uric acid–lowering technologies and intellectual property portfolio across gout, kidney disease, fibrosis, and metabolic disorders. [i]

* See our Important Notice and Disclaimer below for a detailed discussion on compensation, risks, the risks associated with forward looking statements, the need to seek the advice of a professional investment advisor before investing, and more.

🏢 Company Overview

XORTX Therapeutics Inc. Advancing a Diversified Late-Stage Therapeutic Pipeline Targeting Gout, Kidney Disease, and Renal Fibrosis

XORTX Therapeutics Inc. is a pharmaceutical company with multiple clinically advanced therapeutic programs in development, including XRx-026 for the treatment of gout, XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and XRx-101 for acute kidney and other acute organ injury associated with respiratory viral infections.

In addition, XORTX is developing XRx-225, a pre-clinical stage program targeting Type 2 diabetic nephropathy, alongside the recently acquired VB4-P5 program, which is currently at the pre-IND stage of development and targets both rare and prevalent forms of progressive kidney disease.

XORTX continues advancing therapeutic programs focused on aberrant purine metabolism and xanthine oxidase inhibition designed to decrease or inhibit the production of uric acid. Through proprietary therapeutic technologies, expanding intellectual property assets, and pipeline diversification, the company is focused on developing therapies intended to improve outcomes for individuals affected by gout, kidney disease, fibrosis, and related metabolic disorders.

Quick Facts

• Late-stage clinical pharmaceutical company
• NASDAQ Listed: XRTX
• Diversified pipeline: 5 programs
• 700+ patients in clinical studies
• Multiple near-term milestones
• Growing IP portfolio
• $5M recent public offering

Future Growth Opportunities

The XORTX owned and licensed patent family members include claims to cover acute kidney injury (AKI) and other acute organ injuries due to respiratory viral infections including COVID19 – a program which could ultimately be expanded to a larger patient population with unmet medical needs including other viral and sepsis patients.

The value of patents for reformulation or repurposed drugs is additive as is the case of orphan programs given that an FDA grant of orphan drug status would provide the Company with a seven-year marketing exclusivity in the U.S. which would be more than adequate to generate acceptable returns, given the premium pricing available to rare disease opportunities.

7 Years U.S. Exclusivity
10 Years EU & Japan Exclusivity
🔬 Clinical Pipeline

XORTX Therapeutics Inc. Advancing a Diversified Clinical Pipeline Targeting Gout, Progressive Kidney Disease, and Renal Fibrosis

Preclinical
Phase I
Phase II
Phase III
Approval
XRx-026 Gout
505(b)2
XRx-008 Polycystic Kidney Disease
505(b)2
XRx-101 AKI associated with
Respiratory Virus Infection
505(b)2
XRx-225 Diabetic Nephropathy
💊 XRx-026 for Gout

Gout Overview

Common Symptoms of Gout
  • Caused by a Build-Up of Uric Acid in tissues
  • Causes Severe Pain and Discomfort - particularly joints, classic ‘big toe pain’
  • Multiple associated-disease conditions
  • Prevalence has doubled in the last 20 years - 7 million gout patients diagnosed in the US
  • Patients prescribed meds to manage pain and reduce serum Uric Acid concentrations
  • 3-5% of patients are intolerant to allopurinol, the standard of care
📈 XRx-026 for Gout

Market Opportunity: Febuxostat

ROW Febuxostat Sales ($US millions)
  • 2008 – Febuxostat entered the US gout market targeting allopurinol intolerance (~3-5% of patients)
  • 2019 – Received a black box warning; prescriptions dropped
  • 2024 – Febuxostat sales were less than $30M

2025 – No drug currently fills this gap in the gout market

💊 XRx-026 for Gout

Oxypurinol Safety in Allopurinol Intolerant Patients

Over 750 allopurinol-intolerant patients have been successfully treated with oxypurinol.

Proven safe and effective in typical gout and in allopurinol-intolerant gout patients.

Offers patients who don’t respond well to allopurinol an alternative they don’t currently have.

Active metabolite of allopurinol without the same negative effect profile.

Side Effect Incidence

OXPL–213 study*

Allopurinol Oxypurinol
Skin Side Effects 80% 26%
Liver Side Effects 9% 4%
Overall Side Effects 100% 31%
70%

of Allopurinol-intolerant patients get relief from gout symptoms and attacks.

* Patients enrolled in this clinical trial were all ‘allopurinol-intolerant’

⚖️ XRx-026 for Gout

Gout – Competitive Landscape

DRUG STATUS
XRx-026 (xanthine oxidase inhibitor) XORTX Therapeutics Inc.
PRE-NDA READY
Allopurinol (xanthine oxidase inhibitor) Generic
FDA APPROVED
Febuxostat (xanthine oxidase inhibitor) Takeda, various generics
FDA APPROVED (Black Box Warning – acute cardiac death and other side effects)
Uricosuric Agents (probenecid etc.) (reduce reabsorption of uric acid by the kidneys) Various
FDA APPROVED (Increased risk of kidney stone development)
⚖️ XRx-026 for Gout

Regulatory and Clinical Development Plan

XRx-026 Regulatory and Clinical Development Plan
🧪 XRx-026 for Gout

Proprietary Oxypurinol Formulation for Gout

Platform
Technology

Formulation enables maximum drug uptake. Pipeline-in-a-product patented technology

New
Oral Rx

Proprietary and highly scalable CMC approach; once daily oral dosing

Clinical
Trials

Multiple successful trials in >700 patients have demonstrated safety and efficacy.

Clinical
Data

Robust published data supports the therapeutic benefit in gout as well as in other indications.

Oxypurinol – the most effective Uric Acid Lowering Agent available

▼

IP Formulated to Optimize Absorption and Protection

▼

Over 90% Inhibition of the Xanthine Oxidase (XOI) enzyme

Xanthine Oxidase
▼

Reduced Uric Acid Levels

Learn More About XRx-026 →
🔬 XRx-008 for ADPKD

Pipeline – ADPKD Overview

Common Symptoms of ADPKD
  • Causes liver cysts, pain and discomfort
  • Leads to decreased kidney function and ultimately to end-stage kidney disease
  • Associated with increased incidence of neurologic aneurisms, cardiovascular disease
  • 160,000 patients in the US
  • Treatments are limited – Tolvapten ($156,000 annual treatment cost) has a black-box warning for liver toxicity

Renal Fibrosis Accelerates Decline of Kidney Function

  • Chronic kidney disease (CKD) affects an estimated 14% (1 in 7) of adults globally – ~35–37 million individuals in the United States
  • Rare kidney diseases such as autosomal dominant polycystic kidney disease (ADPKD) and lupus nephritis also manifest fibrosis
  • Acute kidney injury can lead to accelerated Renal fibrosis – a failed wound-healing process – resulting in progressive chronic kidney disease and end stage renal failure
  • VB4-P5 – An anti-fibrotic agent – aligns with our strategic focus on developing innovative therapies for progressive kidney disease (Vectus Acquisition)
  • No approved therapies specifically target or reverse kidney fibrosis
Renal Fibrosis - Healthy vs Diseased Kidney
Learn More About XRx-008 →
🧪 XRx-101 for COVID-19

XRx-101 for Coronavirus/COVID-19

The Company is actively reviewing current studies characterizing the outbreak of SARS-CoV-2 (COVID-19). These published reports clearly illustrate that acute kidney injury (AKI) and acute, multiple, organ injury are key factors in the most serious cases of COVID-19 hospitalization and death.

XORTX’s XRx-101 program could be an important therapy with the ability to decrease acute kidney injury and related health consequences associated with respiratory viruses such as Coronavirus infection.

XORTX reported topline results in Nov 2020 that showed that a majority of individuals hospitalized with coronavirus / COVID-19 showed evidence of co-incidence of uric acid concentrations greater than normal as well as acute kidney injury. The severity of the acute kidney injury seen during coronavirus / COVID-19 infection is associated with worse health outcomes and increased mortality.

Learn More About XRx-101 →
💊 XRx-225 for T2DN

XRx-225 for Type 2 Diabetic Nephropathy

Diabetes is prevalent worldwide and represents an epidemic in the US.

T2DN is a kidney disease that affects individuals with diabetes. The number of individuals with diabetes is rising. The total number of adults 20 years of age or older with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030. Approximately 30–40% of individuals with diabetes are estimated to develop diabetic kidney disease.

T2DN affects the kidney’s ability to function normally and is a large unmet medical disease. Diabetic nephropathy affects approximately 12 million US citizens and an estimated 170 million individuals worldwide. Approximately half of all chronic kidney disease and kidney failure has been attributed to diabetic complications. High levels of uric acid have been reported to be an independent risk factor in the progress of kidney disease in these patients, and is associated with increased blood pressure, systemic inflammation, cardiovascular injury, and endothelial dysfunction.

Learn More About XRx-225 →
🏆 Competitive Advantage

XORTX Therapeutics Inc. Positioned with Differentiated Therapeutic Advantages Across Gout and Kidney Disease Markets

XORTX Therapeutics Inc. is advancing a differentiated therapeutic platform supported by proprietary uric acid–lowering technologies, late-stage clinical programs, and expanding kidney disease indications. XRx-026 is positioned to address a significant market gap created following FDA black-box safety concerns associated with febuxostat, while multiple clinical studies involving more than 700 patients have demonstrated safety and efficacy across the company’s oxypurinol-based platform.

The company’s diversified pipeline spanning gout, ADPKD, renal fibrosis, diabetic nephropathy, and acute kidney injury provides exposure to multiple large-market and orphan disease opportunities supported by near-term clinical and regulatory milestones.

XORTX Therapeutics Inc. Competitive Advantages

Near-Term Clinical & Regulatory Milestones [i]

H2 2026
IND submission: gout
H2 2026
Clinical PK Bridging & gout
H2 2026
Completion of CM&C validation: gout
H1 2027
Stability studies initiated: gout
H2 2027
NDA submission: gout

Industry Comparables

2023 Amgen Inc. acquired Horizon Therapeutics plc, developer of a therapy for chronic uncontrolled gout, for approximately $27.8B
2020 Swedish Orphan Biovitrum AB acquired SEL-212 for refractory gout from Selecta Biosciences, Inc. for up to $1.6B
2025 Novartis AG acquired Regulus’ farabursen ADPKD program entering Phase II development for up to $1.7B

These transactions continue to highlight growing strategic and commercial interest across gout, kidney disease, and renal therapeutic markets.

👥 Leadership

Experienced Leadership Team

Dr. Allen W. Davidoff

Allen W. Davidoff, Ph.D.

Chief Executive Officer

Dr. Davidoff has 20 years of drug development experience and is the founder and CEO of XORTX. Allen has a broad range of clinical and regulatory experience and senior management experience in pharmaceutical R&D. Previously, Allen was co-founder, CSO at Stem Cell Therapeutics Corp. which merged with Trillium and thereafter was acquired by Pfizer. Prior to his role at Stem Cell, Allen was Senior Scientist/Head of Pharmacology at Cardiome Pharma Corp. Allen earned his PhD in Cardiovascular Physiology and Biophysics at University of Calgary.

Dr. Stephen Haworth

Stephen Haworth, M.D.

Chief Medical Officer

Dr. Haworth has >25 years of successful global drug development and senior leadership in both “start-up” and Fortune 500 pharmaceutical firms in both the US and Europe. Stephen has a broad clinical and regulatory experience that ranges from nephrology, cardiovascular, and infectious disease. He has extensive regulatory experience with FDA and EMA submissions, as well as licensing and M&A transactions. Stephen holds a MD from University College Hospital Medical School, University of London, having graduated with Honors.

Dr. Taryn Boivin

Taryn Boivin, Ph.D.

Head Chemistry, Manufacturing and Controls (CMC)

Dr. Boivin is a pharmaceutical veteran with >30 years of experience leading all aspects of CMC and related disciplines. Her experience includes multiple worldwide drug submissions, post approval support activities, and commercial supply chain operations. Early in her career, Taryn was among a key group of leaders who established the Glaxo Canada (later GSK) pharmaceutical development organization, and was a pivotal contributor to this world-class research, development, and manufacturing facility. Dr. Boivin has held numerous Senior VP positions in large and small biopharma.

Michael Bumby

Michael Bumby, DVM, MBA

Chief Financial Officer

Dr. Bumby was recently appointed as the Company’s Chief Financial Officer. He has extensive experience in the biotech/pharmaceutical industry from the scientific, regulatory and financial perspectives having worked in multiple Canadian-based publicly traded life sciences companies as well as holding multiple financial roles at Eli Lilly & Company in Canada, the US and in Europe.

Dr. Stacy Evans

Stacy Evans, M.D., MBA

Chief Business Officer (Consultant)

Dr. Evans has >20 years of commercial development and business development experience, including 12 years at Pfizer where he was last responsible for leading transactions across all TAs. Stacy has been consulting at an executive level for small to mid-size private and public biopharma companies for the past 7 years including as part-time Chief Business Officer for Avillion, LLP, a Blackstone-backed late-stage financing and co-development company. Stacy holds a MD from McGill University and an Executive MBA from Columbia University.

📈 Investment Thesis

Investment Highlights

G
O
U
T
SHORT
TIMELINE

XRx-026 for gout targeted for NDA submission by H2 2027

LIMITED
RISK

Safe and effective in over 700 patients

LARGE
MARKET

>$0.7B peak sales opportunity created by a marketed allopurinol alternative receiving a Black Box Warning

PIPELINE

XRx-008 for ADPKD† to begin registration trials with accelerated approval and orphan designation in >$5B market

TEAM

XORTX’s team have a strong history of company building:
Cynapsus Therapeutics acquired for $624M*
Trillium Therapeutics acquired for $2.2B*

📝 In Summary

In Summary

XORTX Therapeutics Inc. (NASDAQ:XRTX) is advancing a diversified late-stage therapeutic pipeline focused on gout, progressive kidney disease, renal fibrosis, diabetic nephropathy, and acute kidney injury across large underserved global healthcare markets.

The company’s proprietary therapeutic platform, expanding intellectual property portfolio, strategic acquisitions, and clinically advanced programs position XORTX within multiple multi-billion-dollar market opportunities supported by significant unmet medical needs and limited approved treatment options.

With XRx-026 approaching important regulatory milestones, XRx-008 advancing toward registration studies for ADPKD, and the VB4-P5 fibrosis program expanding long-term pipeline opportunities, XORTX continues executing a strategy centered on clinical advancement, pipeline expansion, and kidney disease innovation.

Supported by growing industry interest in renal therapeutics, expanding market demand, strategic financing initiatives, and multiple anticipated development catalysts, XORTX is positioning its platform for potential long-term clinical, commercial, and shareholder value growth.

* See our Important Notice and Disclaimer below for a detailed discussion on compensation, risks, the risks associated with forward looking statements, the need to seek the advice of a professional investment advisor before investing, and more.

👁 Investor Focus

Why Investors Are Watching XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is advancing a diversified late-stage therapeutic pipeline targeting large underserved markets across gout, ADPKD, chronic kidney disease, renal fibrosis, diabetic nephropathy, and acute kidney injury. The company’s lead therapeutic candidate, XRx-026, is positioned at the PRE-NDA stage with multiple anticipated regulatory milestones expected through 2027.

XORTX’s proprietary uric acid–lowering technologies, expanding intellectual property portfolio, and strategic pipeline expansion initiatives support exposure to multiple multi-billion-dollar healthcare opportunities driven by significant unmet medical needs and limited approved treatment options.

The company continues advancing growth initiatives through the recently acquired VB4-P5 anti-fibrotic kidney disease program, precision medicine research activities, and development programs targeting progressive kidney disease and metabolic disorders.

Supported by growing industry interest in renal therapeutics, comparable sector acquisitions, expanding clinical development activities, and multiple near-term catalysts, XORTX is positioning its therapeutic platform for potential long-term clinical, commercial, and shareholder value growth.

* See our Important Notice and Disclaimer below for a detailed discussion on compensation, risks, the risks associated with forward looking statements, the need to seek the advice of a professional investment advisor before investing, and more.

Investor Focus
📰 News Article

Latest News

GlobeNewswire
May 19, 2026

XORTX Announces Closing of US$5 Million Public Offering

 Read Article →
GlobeNewswire
.

XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

 Read Article →
GlobeNewswire
January 1, 2026

XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

 Read Article →

Source

i - https://d1io3yog0oux5.cloudfront.net/_aa1c1fed100fcceb2ad90f27c2c12438/xortx/db/856/7722/pdf/XORTX+Therapeutics+Investor+Presentation+June+2026.pdf

ii - https://www.xortx.com/pipeline

iii - https://finance.yahoo.com/sectors/healthcare/articles/xortx-announces-closing-acquisition-vectus-210000963.html

IMPORTANT NOTICE AND DISCLAIMER

Copyright 2026 © Stocks.News is owned and operated by IR Agency LLC.

To more fully understand any subscription, website, application, product, or other service (“Services”) including Stocks.News owned or operated by IR Agency LLC (together, with its affiliates, owners, and control persons, the “Publisher”), please review our full disclaimer and other policies located at https://stocks.news/privacy-policy-disclaimer/

Issuer-paid advertisement. [XORTX Therapeutics Inc.] (“XRTX” or the “Company”) has a current agreement to pay Publisher Two Million Five Hundred Thousand Dollars Cash ($2,500,000) in cash for marketing services including communicating information about the Company to the Public. This advertorial (“advertisement” or “Advertorial”) is part of those issuer-paid marketing services. The contract with XRTX was effective on 9/08/2026 and continues for a 10 days (the “Term”) unless it is terminated by written notice of either party prior to the end of the Term or extended. As a result of this advertisement and other marketing efforts, Publisher also may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, Publisher holds no securities of the Company and does not intend to purchase any securities during the Term. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of XRTX, increased trading volume, and possibly an increased share price of the XRTX’s securities, which may or may not be temporary and decrease once the marketing services have ended.

For Educational and Information Purposes Only; Not Investment Advice. This advertisement is for educational, informational and entertainment purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Publisher cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of this Company or any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the Company that is the subject of the Advertorial or any other companies mentioned in this Advertorial, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this Advertorial or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.

SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in the securities of the Company profiled in the Advertorial or any securities of the companies mentioned in this advertisement should do so with caution. Although this advertisement focuses on the positive features of the Company profiled and its securities, you must keep in mind that investing or transacting in these or any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement at most as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.

Not an Investment Advisor or Registered Broker. Neither Publisher, or any of their owners, employees or independent contractors is currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.

USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Publisher does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the Company profiled in the Advertorial at https://www.sec.gov/edgar/search/#/ciks=0001729214&entityName=XORTX%2520Therapeutics%2520Inc.%2520(XRTX)%2520(CIK%25200001729214)

TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.

COMPENSATION

The owners of IR Agency LLC who also are the publishers of this Advertorial have been paid Two Million Five Hundred Thousand Dollars Cash ($2,500,000) via bank wire transfer directly from the Issuer XORTX Therapeutics Inc. (NASDAQ: XRTX) for a 10 individual Marketing Days of distribution of marketing program regarding XRTX with a start date of 9/08/2026. This Advertorial is a part of that marketing program. The owners do not own stock in XRTX. See our important Notice and Disclaimer below for a detailed discussion on compensation.